Bio­Marin ex­ecs dis­cuss some eye-pop­ping num­bers for the price of val­rox — but haven't we heard this be­fore?

Robert Baf­fi Bio­Marin

SAN FRAN­CIS­CO — Bio­Marin got some con­sid­er­able at­ten­tion from the Wall Street Jour­nal to­day with its rev­e­la­tion that CEO JJ Bi­en­aimé has been think­ing about charg­ing $2 mil­lion to $3 mil­lion for the com­pa­ny’s new gene ther­a­py for he­mo­phil­ia A, val­rox, which is the lead drug in the race for a pi­o­neer­ing FDA ap­proval.

It’s an im­por­tant dis­cus­sion, and we’re glad to see it play out in the gray la­dy of Street speak, which has a big reach. But close ob­servers will note that this isn’t a new num­ber. Bi­en­aime and his ex­ec­u­tive team dis­cussed that very same range back in Feb­ru­ary dur­ing their Q4 call, which we re­port­ed on. Maybe oth­ers buzzed about it as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER